ArticleThe Journal of thoracic and cardiovascular surgery2020
Early outcomes with durable left ventricular assist device replacement using the HeartMate 3.
Article in The Journal of thoracic and cardiovascular surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The Impact of Obesity on Durable Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.Artificial organs · 2026Pooled it
- Left ventricular assist device exchanges: A safe and effective strategy in the era of limited organ availability.The International journal of artificial organs · 2025Article
- Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis.SAGE open medicine · 2024Review
- Device Exchange to HeartMate 3 LVAD: Impact of Previous Pump Model on Clinical Outcomes.Annals of thoracic surgery short reports · 2023Article
- Left ventricular assist device exchange: a review of indications, operative procedure, and outcomes.Indian journal of thoracic and cardiovascular surgery · 2023Review
- Left ventricular assist device exchange from HeartMate II to HeartMate 3 in an Asian patient-a case report and literature review.Journal of cardiothoracic surgery · 2023Review
- Left Ventricular Assist Devices: A Primer For the General Cardiologist.Journal of the American Heart Association · 2022Review
- Approaches to ventricular assist device exchange: Resternotomy versus limited incisions.JTCVS techniques · 2022Article
- Article
- Immobilization-induced symptomatic hypercalcemia treated with zoledronate in a child with a left ventricular assist device.Annals of pediatric endocrinology & metabolism · 2021Article
- Hemostatic Challenges in Pediatric Critical Care Medicine-Hemostatic Balance in VAD.Frontiers in pediatrics · 2021Review
- Reducing ECG Artifact From Left Ventricular Assist Device Electromagnetic Interference.Journal of the American Heart Association · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe HeartMate 3 (HM3) left ventricular assist device (LVAD) (Abbott, Inc, Chicago, Ill) is a fully magnetically levitated centrifugal implantable pump used to treat patients with chronic heart failure. The MOMENTUM (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) trial demonstrated that patients treated with the HM3 experienced reduced need for reoperation for LVAD replacement compared with a control group receiving an axial flow design, Heartmate II (Abbott, Inc). However, there are few reports of using HM3 as the replacement pump in patients who already are supported by a durable LVAD and experience a device-related complication necessitating replacement.
methodsAn institutional LVAD database was used to identify 19 consecutive patients who underwent pump replacement to HM3 (group 1) versus 85 consecutive control patients who underwent pump replacement to either Heartmate II or HeartWare Ventricular Assist Device (Medtronic Inc, Minneapolis, Minn) (group 2), at a single institution from January 2010 to August 2018. Patient baseline characteristic and outcomes were obtained from a prospectively maintained database. The primary endpoint was a composite of freedom from death or need for another replacement surgery.
resultsThere was no difference between the groups in heart failure etiology, indication for replacement, as well as the average days on the previous pump or the type of previous pump. The HM3 group did have a significantly greater body mass index (37 vs 31.6 P = .01), a greater number of previous LVAD implants (36.8% vs 5.9%, had 2 previous LVADs, P < .001), and a greater number of previous sternotomies (31.6% vs 7.1%, had 3 previous sternotomies, P = .001). No difference was found between the groups in terms of postoperative adverse event rates. With regards to the primary endpoint, the patients with HM3 replacements (group 1) versus group 2 experienced significantly greater freedom from either death or need for another replacement during the follow-up period (P = .039). During follow-up, there were no thrombosis events for the patients who received replacement with HM3.
conclusionsLVAD replacement with HM3 can be performed safely and may be considered as the pump of choice in patients requiring LVAD replacement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.